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Abstract
( )T-cell acute lymphoblastic leukemia T-ALL is charac-
terized by the presence of differentiation-inhibited pro–
and pre–T-cell blasts. The p16INK4a tumor suppressor
gene has been shown to be frequently deleted in hu-
man T-ALL cases. Deletion of p16INK4a may be associ-
ated with poor prognosis and relapse of the disease.
Radiation-induced murine T-ALL in C57B1 / 6 mice
shares pathogenetic and molecular characteristics with
the human disease. We used the murine disease as a
model to study the status of the INK4/ARF gene locus
and to examine the effect of p16INK4a-re-expression in
T-ALL cells on their leukemic potential in vivo. In 9 of
17 radiation-induced murine T-ALL cell lines, the
p16INK4a protein was not expressed as determined by
immunoblotting. Southern blot analysis revealed ho-
mozygous deletions of the p16INK4a gene locus in three
of the nine lines, along with the genes encoding p15INK4b
and p19ARF. Transduction of p16INK4a-negative T-ALL
lines with retrovirus encoding p16INK4a significantly in-
hibited their in vitro proliferation by inducing G -arrest.1
Importantly, re-expression of p16INK4a in p16INK4a -nega-
tive T-ALL cells obliterated the induction of lethal dis-
seminated leukemia in syngeneic mice. This is the first
demonstration that re-establishment of p16INK4a ex-
pression is critical for in vivo growth regulation of
T-ALL cells.
Keywords: p16INK4a, T-cell acute lymphoblastic leukemia, retroviral gene transfer,
tumor suppression in vivo.
Introduction
The tumor suppressor protein p16INK4a modulates the cy-
( )clin-dependent kinase CDK 4/6-cyclin D–mediated phos-
( )phorylation of the retinoblastoma protein pRB , thereby
[ ]regulating the G - to S-phase transition of the cell cycle 1 .1
Inactivation of p16INK4a is a frequent event in tumors and
tumor cell lines and can occur by three known mechanisms:
homozygous deletion, point mutations, or transcriptional si-
[ ]lencing by promoter hypermethylation 2 . In T-cell acute
( )lymphoblastic leukemia T-ALL , homozygous deletion of
p16INK4a, located on chromosome 9p21, is found in up to
80% of patient samples, whereas point mutations and pro-
[ ]moter methylation are infrequent events 3–7 . Furthermore,
homozygous deletion of p16INK4a may be associated with
[ ]poor prognosis and relapse of the disease 7–9 , often
requiring additional therapeutic measures such as bone
( )marrow transplantation BMT .
In addition to p16INK4a, two other genes are often lost
INK4b [ ]during deletion of the 9p21 locus: The p15 gene 10 ,
whose product also functions as an inhibitor of CDK4/
ARF [ ]6-cyclin D complexes, and p14 11 . In T-ALL, deletion
of the p15 INK4b gene is less frequent than that of p16 INK4a
[ ] INK4b5,7 , although the promoter of the gene encoding p15
[ ]is often methylated 5,12 . ARF, which has a partially over-
lapping coding sequence with p16INK4a but encodes a
unique protein, increases stability and activity of the p53
[ ]protein 13–16 and acts as a tumor suppressor indepen-
INK4a [ ]dent of p16 17 . Recently, Gardie et al. reported that
the p14ARF gene was deleted or disrupted in all 149 human
T-ALL cases with rearrangements of the 9p21 locus stud-
ied, whereas the p15 INK4b and the p16 INK4a genes re-
[ ]mained intact in 21 and 4 cases, respectively 18 .
Analysis of radiation-induced thymic leukemias from
C57B1/6 mice has shown that these tumors share many
characteristics with human T-ALL. Both are composed of
[ ]pro- and pre-T-cells blocked in differentiation 19,20 . An-
other similarity between human and murine T-ALL is the
presence of mutations in p53, which occur in 30% to 50% of
human T-ALL cases and are associated exclusively with the
[ ]relapse phase of the disease 21 . Similarly, 60% of murine
T-ALL samples tested had mutations in p53. These muta-
tions occurred in leukemic animals in which the disease had
spread to peripheral organs, whereas those tumors that
[ ]were confined to the thymus harbored wild-type p53 22 .
The numerous similarities between human and murine
T-ALL make the murine disease a suitable model for study-
ing the pathogenesis of T-ALL and for testing potential
therapies. Here we report that, as in the human disease,
loss of p16INK4a is a common event in murine T-ALL. Using
retroviral gene transfer, we demonstrate that restoration of
p16INK4a expression in murine T-ALL cells that have lost
expression of the endogenous protein dramatically inhibits
their growth in vitro by inducing G -arrest. Cell-cycle arrest1
by overexpression of the exogenous protein was also ob-
served in a cell line that retained expression of the endoge-
nous protein. Importantly, we found that restoration of
Abbreviations: BMT, bone marrow transplantation; GFP, green fluorescent protein;
MSCV, murine stem cell virus.
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p16INK4a expression in T-ALL cells significantly inhibited
their ability to induce lethal disseminated leukemia in syn-
geneic mice.
Materials and Methods
Cell Culture
We maintained 293 human embryonic kidney cells, Balb/
c3T3, and D384, a human glioblastoma cell line, in Dul-
(becco-Vogt modified Eagle’s medium DMEM, Sigma, St.
) (Louis, MO with the addition of 10% fetal calf serum Hy-
)Clone, Logan, VT . All T-ALL cell lines were established
from thymomas developed in C57B1/6 mice that had been
treated at 4 to 6 weeks of age with 4 weekly doses of 170
[ ]cGy ionizing radiation 19,20,23 . The T-ALL lines were
grown in this medium with the addition of nonessential
( )amino acids Irvine Scientific, Irvine, CA , 4 mmol / L
( )L-glutamine Irvine Scientific , 150 mmol/L asparagine, and
( )100 mmol/L thioglycerol Sigma .
Southern Blot Analysis
Genomic DNA was extracted from the indicated murine
T-ALL cell lines or normal mouse tissue and was digested
with either Bam HI for analysis of the p15INK4b, p16INK4a,
and p19ARF loci or with Eco RI for analysis of the Rb gene;
10 mg of each sample was fractionated by size on a 0.7%
agarose gel, transferred to nylon membrane, and hybridized
[32 ]with a P -labeled probe of either full-length mouse
INK4b ( INK4b) INK4ap15 SalI fragment of pBS-p15 , p16
( INK4a) ARFEcoRI-Xho1 fragment of pBSp16 , or p19
( ARF)EcoRI-Xho1 fragment of pcDNA-p19 cDNA. For Rb,
the blots were probed with a 1.2-kb fragment of the 3X end
of the mouse Rb cDNA or a 1.9-kb fragment of the 5X end
isolated from a BamHI and BglII digestion of the pECE-B/
X-HA vector.
Immunoprecipitation and Immunoblot Analysis
For analysis of the endogenous murine p16INK4a protein,
6 (6=10 cells were resuspended in 1.0-mL lysis buffer 150
mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5; 0.5% Nonidet
P-40; 500 mmol/L phenylmethylsulfonyl fluoride; and 100
)U/mL aprotinin , centrifuged at 12,000 rpm for 10 minutes
at 48C, and precleared with protein A sepharose. One half
of each lysate was incubated with the anti-simian virus 40
[ ]Large T antigen antibody, pAb 419 24 as a nonspecific
INK4a (control, or with the monoclonal p16 antibody M-156 2
)mg per sample; Santa Cruz Biotechnology, Inc overnight at
48C. Bound proteins were recovered on protein A sepharose
( )preblocked with 3% nonfat dry milk , washed, resolved on
( )a 15% sodium dodecyl sulfate SDS polyacrylamide gel,
and transferred to nitrocellulose membranes, following stan-
(dard protocols. The membranes were blocked in TTBS 140
mmol/L NaCl, 20 mmol/L Tris, 5 mmol/L HCl, and 0.1%
)Tween-20, pH 7.6 containing 5% nonfat dry milk, washed
(with TTBS, and incubated with the M-156 antibody 2 mg/
)mL overnight at 48C. Membranes were then washed as
before, incubated with peroxidase-conjugated donkey
( )anti-rabbit IgG Amersham for 1 hour at room temperature
and washed in TTBS. Bands were visualized with ECL
(Western blot detector reagents Amersham Life Science,
)Arlington Heights, IL .
( )For analysis of the murine stem cell virus MSCV –
expressed human p16INK4a, a polyclonal antihuman
INK4a (p16 antibody Pharmingen, San Diego, CA; 2 mg for
)immunoprecipitation and 1:1000 dilution for immunoblot
was used. Binding of human p16INK4a to the endogenous
mouse CDK4 protein in infected cells was demonstrated by
immunoprecipitating human p16INK4a and immunoblotting
(with the monoclonal anti-CDK4 antibody ACD1 1.5 mg/mL;
)Pharmingen , which recognizes both murine and human
CDK4.
pRB was analyzed by lysing cells in SDS-polyacrylamide
( ) (gel electrophoresis PAGE sample buffer 50 mmol/L Tris,
pH 6.8; 10% glycerol; 2% SDS; and 1 mg/mL bromphenol
)blue , boiling 5 minutes, pelleting cell debris by centrifuga-
tion for 10 minutes at 208C, resolving on a 7.5% SDS-poly-
acrylamide gel, and transferring to nitrocellulose. Mem-
branes were probed with the anti-pRB antibody G3-245
( )Pharmingen and the bands visualized by chemilumines-
cence.
Viral Vectors, Virus Production, and Infection
( )MSCV–green fluorescent protein GFP was constructed
[ ] INK4aas described previously 25 . MSCV-hp16 was con-
structed by removing the human p16INK4a cDNA from
INK4a [ ]pCLp16 26 with Eco RI and XhoI and cloning it into
[ ]these sites of MSCV 2.1 27 . Ecotropic virus was produced
by cotransfecting late-passage 293 cells with the viral vec-
[ ]tors and the pCL-Eco packaging vector 28,29 . Viral titers
were determined by limiting dilution of virus on Balb/c3T3
cells in the presence of polybrene and selection for 10 days
with 350 mg/mL G418, resulting in titers of 107 cfu/mL
( ) 6 7 ( ) 6MSCV , 2=10 to 10 cfu/mL MSCV-GFP and 2=10
6 ( )to 6= 10 colony-forming units CFU per milliliter
( INK4a)MSCV-p16 . Cell lines were infected by culturing three
times for 2 to 4 hours each in viral supernatant, yielding a
final multiplicity of infection of 5.
Proliferation Assays
T-ALL 4, 5, and 68 were infected with ecotropic MSCV,
MSCV-GFP, or MSCV-hp16INK4a or were incubated in
medium containing 8 mg/mL polybrene. At 10 hours after
the start of infection, cells were plated in triplicate 96-well
tissue culture dishes with 12 wells per infected line and 104
cells per well. At 28, 52, and 76 hours after infection, the
[3 ]cells on one plate were labeled with 50 mCi/mL H -thymi-
(dine 6.7 Ci /mmol, ICN Pharmaceuticals Inc., Costa Mesa,
)CA for 6 hours and then harvested onto glass fiber filters
for scintillation counting.
Cell Cycle Analysis
T-ALL 4, 5, and 68 were infected with ecotropic MSCV,
MSCV-GFP, or MSCV-hp16INK4a or were incubated in
medium containing 8 mg / mL polybrene. MSCV-GFP
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Table 1. Status of Tumor Suppressor Genes in Murine T-ALL Cell Lines.
bCell line p15 gene p16 gene p 16 protein ARF exon 1b ARF mRNA Rb gene pRb protein p53
1 q q q q q q Nd Mut
4 q q - q - q q Mut /wt
5 Del Del - Del ND q q Wt
10 Del Del ND Del ND q ND Mut
11 q q q q q q ND Mut
20 q q - q q q ND Wt
42 q q - q q q ND Wt
43 q q q q q q ND Mut
44 q q q q q q ND Mut
46 Del Del - Del - q ND Wt
a63 q q/Del - q q q ND Wt
65 q q - q q q ND Wt
67 q q - q q q ND Wt
68 q q q q q q q Mut
71 q q q q ND q q Mut
114 q q ND q ND q ND Mut
121 q q ND q ND q ND Mut
NOTE. Gene status was determined by Southern blot analysis. Protein expression was assayed by immunoprecipitation and Western blot analysis and
mRNA expression by RT-PCR analysis.
aSouthern blot analysis indicates that one allele of p16 in T-ALL 63 is partially deleted.
b ( )Data from Hsiao et al., 1995 by sequence analysis .
( )q, gene /mRNA /protein detected; del, deletion; -, mRNA /protein not detected; ND, not determined
infected cells were used to monitor infection efficiency,
which averaged 70% of total cells as determined by fluores-
(cence-activated cell sorter FACS; Becton Dickinson and
) 6Company analysis. On days 1 through 3 after infection, 10
cells from each infected population were resuspended in
( )medium containing 20 mmol/L bromo-deoxyuridine BrdU .
Cells were incubated for 2 hours at 378C, fixed in 70%
ethanol, and stored at 48C for at least 24 hours. After
denaturation in 2.5 mol/L HCl, FITC-labeled BrdU antibody
was added for 30 minutes, and cells were washed, stained
( ) (in 500 mL propidium iodide PI solution 100 mg/mL PI,
0.1% Triton X100, 0.1 mmol/L EDTA in phosphate-buffered
( ) (saline PBS , and analyzed on a FACScan Becton Dickin-
)son .
INK4a ( ) ( ) ( )Figure 1. Expression of p16 A and pRB B in T-ALL cell lines. A Lysates from murine T-ALL cell lines were immunoprecipitated by using a
monoclonal antibody that recognizes mouse p16 INK4a or PAb 419 as a nonspecific control. Samples were resolved by SDS-PAGE and subjected to
INK4a ( )immunoblot analysis using the same p16 antibody. B Lysates from murine T-ALL cells were subjected to immunoblot analysis with the anti-Rb
( )antibody G3-245 Pharmingen . Lysates from Balb/c 3T3 cells were used as a positive control. Both the hypo- and hyperphosphorylated forms of pRB
can be seen in each sample. Size markers are indicated on the left.
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In Vivo Suppression Experiments
T-ALL 5 cells were infected with ecotropic MSCV-GFP or
MSCV-hp16INK4a virus as described. At 24 hours after in-
( )fection, cells were selected with G418 1 mg/mL for 24
hours, washed, and resuspended in PBS; 105 cells were
injected into the tail vein of female C57B1/6 mice. Sixteen
mice were injected with MSCV-GFP–infected cells, and 15
mice received MSCV-hp16INK4a–infected cells. Animals
were monitored for 100 days for signs of disseminated
leukemia including ruffled fur, weight loss, swollen ab-
domen, and lethargy, and they were sacrificed at signs of
severe illness. Animal studies had been approved by the
University of California San Diego Animal Subjects Commit-
tee.
Reverse Transcriptase Polymerase Chain Reaction Analy-
sis
Total RNA was isolated from the liver and spleen of four
final-stage animals injected with MSCV-hp16INK4a–infected
(T-ALL 5 cells by using RNA Stat-60 Tel-TEST ‘‘B,’’
)Friendswood, TX , following the manufacturer’s instructions.
RT was performed with 1mg of tumor cell RNA per sample.
Thirty nanograms of RNA from MSCV-hp16INK4a–infected
T-ALL 5 cells was used as a positive control and 1 mg of
RNA from uninfected T-ALL 5 cells as a negative control.
One quarter of the RT reactions was used as a template for
( )polymerase chain reaction PCR . For amplification of the
human p16INK4a cDNA, the following primers were used:
Forward primer—5X-AA CAG TCGACG GGC GGC GGG
GAG CAG CAT-3X; and reverse primer—5X-TT GGA TCC
GGG ATG TCT GAG GGA CCT TCC-3X. These primers
were specific for human p16INK4a cDNA and did not amplify
the mouse homologue. PCR was performed in the presence
of 1.5 mmol/L MgCl , 200 mmol/L dNTP, and 10% dimethyl2
( )sulfoxide DMSO by using the following protocol: 958C, 5
minutes; 35 cycles at 948C, 1 minute; 698C, 1 minute; 728C,
1 minute; 728C, 5 minutes. RT-PCR of mouse b-actin mRNA
served as a control for intact RNA. PCR was performed by
using the forward b-actin primer 5X-TT GTA ACC AAC TGG
GAC GAT ATG G-3X and the reverse b-actin primer 5X-GAT
CTT GAT CTT CAT GGT GCT AGG-3X in the presence of
2.2 mmol/L MgCl and 200 mmol/L dNTP and the following2
protocol: 958C, 5 minutes; 30 cycles at 948C, 1 minute;
588C, 1 minute; 728C, 1 minute; 728C, 10 minutes.
Genomic DNA was extracted from leukemic spleens of
the same four animals. DNA from normal liver tissue of a
C57B1/6 mouse served as negative control. PCR screening
for the presence of the provirus was carried out as de-
scribed by using the same hp16INK4a -specific primers. Con-
trol PCR was performed with primers amplifying a 266-bp
(fragment of intron6-exon7 of murine p53 forward primer
5X-TGC CGA ACA GGT GGA ATA T-3X and reverse primer
X X)5 -AGG GAT CCA GTG TGA TGA TGG TAA G-3 in the
presence of 1.5 mmol/L MgCl and 200 mmol/L dNTP at2
958C for 5 minutes, for 30 cycles at 938C for 1 minute, at
588C for 1 minute, at 708C for 1 minute, and at 728C for 10
minutes.
For screening for the p19ARF transcript, total RNA was
isolated from the T-ALL cell lines as described; 200-ng RNA
was subjected to RT, and 2 mL of the reaction was used as
a template for PCR. Forward primer 5X-CTT GGT CAC TGT
GAG GAT TC-3X and reverse primer 5X-TGA GGC CGG
ATT TAG CTC TGC TC-3X were used to amplify templates
in the presence of 2 mmol/L MgCl and 200 mmol/L dNTP2
at 958C for 5 minutes; 35 cycles at 948C for 1 minute, at
658C for 45 seconds, at 728C for 1.5 minutes, and at 728C
for 10 minutes.
Results
Deletions of the p15 INK4b, p16 INK4a, and 19 ARF Genes in
Murine T-ALL
Guided by the loss of p15INK4b, p16INK4a, and p14ARF in
[ ]human T-ALL 5,18 , we have screened a panel of murine
T-ALL lines by Southern blot analysis to determine the
( )status of these genes in the murine disease Table 1 . In 17
lines studied, we found that homozygous deletions of the
p16INK4a gene occurred in three cases. Additionally, in the
Figure 2. Expression of hp16 INK4a in MSCV-hp16 INK4a– infected
( ) INK4a ( )T- ALL cells A and binding of human p16 to murine CDK4 B .
( ) INK4aA Lysates from MSCV-hp16 – infected and from uninfected
T- ALL 4, T- ALL 5, and T- ALL 68 cells were immunoprecipitated with a
polyclonal antibody that specifically recognizes human but not murine
p16 INK4a or with pAb 419 as a nonspecific control. Immunoprecipitates
were resolved by SDS-PAGE and subjected to immunoblot analysis
with the same p16 INK4a antibody. Uninfected cells were used as nega-
tive controls and the human glioblastoma cell line D384 was used as a
INK4a ( )positive control for hp16 . B Lysates from infected and uninfected
( )T- ALL 68 cells were immunoprecipitated as in A , and samples were
subjected to immunoblot analysis with a monoclonal antibody that binds
( )murine and human weakly CDK4. D384 was used as a control for
binding of human CDK4 by human p16 INK4a. Size markers are indi-
cated on the left.
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T-ALL 63 line, one allele of the gene had undergone partial
deletion. Because the p16 INK4a and p19 ARF genes share
common exons, the deletion of the p16INK4a locus sug-
gested that p19ARF was also deleted. However, because
the translation product of p19ARF exon1b exhibits the growth
ARF [ ]arrest-inducing activity of the full-length p19 protein 15 ,
we also assayed the status of that exon by Southern blot
analysis. We found that p19ARF exon1b was deleted in the
same three lines that had also lost the p16INK4a and the
p15INK4b locus. These results indicate that deletions of
p15INK4b, p16INK4a, and p19ARF do occur in murine T-ALL
but at a lower frequency than that reported for human
T-ALL.
Expression of the p16 INK4a Protein and p19 ARF Transcript
in Murine T-ALL
To establish whether cells with an intact p16 INK4a gene
expressed the p16INK4a protein, immunoprecipitation and
Western blot analysis of selected T-ALL lines were per-
formed. Figure 1A shows that the p16INK4a protein was not
produced in 6 out of 12 lines that retained the gene locus.
Thus, although only 3 of 17 murine T-ALL lines have deleted
the p16 INK4a gene, at least 9 of the 17 did not express the
protein. To determine if this was due to transcriptional
silencing associated with hypermethylation of the p16INK4a
promoter, we treated the cell lines with the methyltrans-
X ( ) [ ]ferase-inhibitor 5-aza-2 -deoxycytidine 5-aza-CdR 30 .
Nontoxic concentrations of the compound that allowed the
cells to survive for more than 3 days were in the range of 20
to 50 nmol/L, a concentration insufficient to demethylate the
p16INK4a promoter. Indeed, treatment of the cells with this
low concentration of 5-aza-CdR for 6 days did not induce
INK4a ( )p16 expression data not shown . Hence, the mecha-
nism by which p16INK4a protein synthesis is inhibited in
these T-ALL lines remains unresolved.
Although technical difficulties with the available antibod-
ies against p19ARF, which often yield uninterpretable re-
sults, precluded us from assaying for p19ARF protein,
RT-PCR analysis on mRNA extracted from the T-ALL cell
(lines revealed that one line with an intact ARF gene T-ALL
)4 did not express the transcript. The rest of these lines
ARF ( )expressed p19 mRNA Table 1 .
Status of Rb in Murine T-ALL
It has been reported that some human tumor cells that
retain p16INK4a expression have disrupted the p16INK4a-Rb
[ ]pathway through the loss of the Rb gene 1,26,31 , whereas
[ ]this inverse correlation does not apply in mouse 32 . To
investigate the status of the Rb gene we screened the 17
T-ALL lines by Southern blot analysis. The results demon-
strated that the Rb gene was intact in all lines examined
( )Table 1 . Western blot analysis revealed expression of both
hypo- and hyperphosphorylated pRB in four of the lines
INK4a ( )regardless of their p16 status Figure 1B . The two
forms of pRB were confirmed in an independent Western
blot analysis, including serum-starved mouse embryonic
(fibroblasts as a control for hypophosphorylated pRB data
)not shown .
Inhibition Of T-ALL Cell Proliferation in Vitro by p16 INK4a
Gene Transfer
( )Three cell lines T-ALL 4, T-ALL 5, and T-ALL 68 were
infected with MSCV-p16INK4a and selected for neomycin
resistance. Expression of human p16INK4a in all three cell
lines was demonstrated by immunoprecipitation and West-
ern blot analysis. The level of exogenous hp16INK4a expres-
INK4a ( ) ( ) ( )Figure 3. MSCV-hp16 suppresses the proliferation of infected murine T-ALL cell lines. T-ALL 4 A , T-ALL 5 B , and T-ALL 68 C were infected
[3 ] [ 3 ]as described. The rate of proliferation was determined by labeling with H -thymidine for 6 hours on the indicated days. The amount of H -thymidine
incorporated for each infected cell line is plotted versus the number of days after infection. The status of endogenous p16 INK4a is indicated for each
line.
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sion in T-ALL 4 and T-ALL 5 was significantly lower than
( )that observed in T-ALL 68 Figure 2A , reflecting the nega-
tive selective pressure against high levels of hp16INK4a in
the former two cell lines, as described in the following
section.
Because the key biochemical role of p16INK4a in the cell
is to bind to CDK4 and CDK6, preventing these proteins
from complexing with cyclin D, we determined that murine
CDK4 coprecipitates with exogenous human p16INK4a, as is
shown for infected T-ALL 68 cells in Figure 2B. We also
tested MSCV-hp16INK4a–infected T-ALL 4 and T-ALL 5 for
the binding of hp16INK4a to murine CDK4 but were unable
to detect any CDK4, probably due to the low level of
hp16INK4a precipitable from these cells.
To examine the biological effect of hp16 INK4a gene
transfer, we assayed the proliferation rate of infected T-ALL
4, T-ALL 5, and T-ALL 68 cells by pulse-labeling with
[3 ]H -thymidine. The fraction of infected cells as measured
by GFP expression in MSCV-GFP–infected T-ALL 4, T-ALL
5, and T-ALL 68 cells was 79%, 65%, and 65%, respec-
INK4a ( ) ( ) ( )Figure 4. Expression of human p16 in murine T-ALL cell lines induces G -arrest. T-ALL 4 A , T-ALL 5 B , and T-ALL 68 C cells were infected1
as described. On days 1, 2, and 3 after infection, the fraction of cells in the G - , S- , and G -phases of the cell cycle was determined by BrdU1 2
incorporation and staining with PI. Those cells with a DNA content less than 2N as determined by PI staining were considered to be sub G . The status1
of endogenous p16 INK4a is indicated for each line.
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( )tively data not shown . The proliferation of T-ALL 4 and
T-ALL 5 was significantly reduced by their infection with
MSCV-hp16INK4a, compared to control- or mock-infected
cells. There was also a modest decrease in the proliferation
of T-ALL 68 in response to infection with MSCV-hp16INK4a
( ) (Figure 3 . These results agree with the lack T-ALL 4 and
) ( ) INK4a5 or presence T-ALL 68 of endogenous p16 . In all
three lines, the rate of proliferation increased on the third
INK4a ( )day after infection with MSCV-hp16 Figure 3 , proba-
bly due to the presence and continuing proliferation of
uninfected cells.
p16 INK4a-Gene Transfer Mediates Inhibition of Murine T-ALL
Cell Proliferation by Inducing G -Arrest1
To determine the mechanism by which T-ALL cell prolif-
eration was inhibited by hp16INK4a expression, we
pulse-labeled the infected cells with BrdU and stained with
PI. The fraction of infected cells as assayed by GFP expres-
sion was 68% of T-ALL 4, 95% of T-ALL 5, and 79% of
( )T-ALL 68 cells data not shown . The fraction of T-ALL 4
and T-ALL 5 cells in the G -phase on days 1 and 2 after1
infection with MSCV-p16INK4a was doubled compared with
control- and mock-infected cells, whereas the S-phase frac-
tion was reduced from 40% to about 10%, as determined by
( ) (FACS Becton Dickinson and Co analysis Figure 4A and
) INK4aB . Similarly, infection of T-ALL 68 with MSCV-hp16
induced G -arrest, but to a lesser degree than that observed1
( )for T-ALL 4 and T-ALL 5 cells Figure 4C . The different
extent to which these cells were inhibited in proliferation
( ) (see Figure 3C as compared with G -arrested cells Figure1
)4C is at least partly due to the higher infection efficiency of
the cells used for cell cycle analysis. The reduced S-phase
fraction of untreated T-ALL 68 cells on day 3 may reflect
overcrowding caused by the rapid proliferation of this cell
line.
Although G -arrest was a mechanism by which1
p16INK4a-encoding virus inhibited the growth of T-ALL cells,
[ ]possible induction of apoptosis 33 was also tested by
using two different markers for apoptosis. Comparison of
both the sub-G fraction and the fraction of Annexin V-posi-1
tive cells of the MSCV-hp16INK4a infected with the
control-infected T-ALL 4– and T-ALL 68–cell populations
revealed no significant difference in the number of apoptotic
cells. Although there was an increase in the sub-G fraction1
INK4a ( )among hp16 -infected T-ALL 5 cells Figure 4B , which
suggested the induction of apoptosis in 16% of the cells, the
results indicate that the inhibition of T-ALL cell proliferation
by the expression of exogenous p16INK4a takes place mainly
through the induction of G -arrest.1
Inhibition of Leukemia-Cell Proliferation In Vivo by Expres-
sion of Exogenous hp16 INK4a
(Previously, we found that infection of T-ALL 5 cells p53
)wt/wt with wild-type p53-encoding vectors did not affect
their growth in vitro nor reduce their ability to induce
( )leukemia in vivo Norris and Haas, unpublished . T-ALL 5
cells lack both copies of the gene encoding p16INK4a. Hence,
we tested whether infection with virus encoding p16INK4a
would inhibit the capacity of T-ALL 5 cells to cause leukemia
in vivo. As shown in Figure 5A, infection of T-ALL 5 with
MSCV-hp16INK4a virus significantly reduced the lethality of
( )leukemia in the recipients P- .01, chi-squared test com-
pared with cells infected with MSCV virus encoding GFP.
The fraction of infected cells was 94%, as determined by
the fraction of GFP-expressing MSCV-GFP–infected cells.
Figure 5. Infection of T - ALL 5 with MSCV - hp16 INK4a suppresses
( )lethal leukemia in C57B1/6 mice. A Cumulative lethality in mice in-
jected with control- or MSCV-hp16 INK4a–treated T- ALL 5 cells. None
of the 16 mice injected with MSCV-GFP– infected cells were alive 30
days after injection, whereas 7 of 15 mice injected with
MSCV-hp16 INK4as– infected cells were still alive 100 days after injec-
( )tion and showed no signs of disease. B RT-PCR was performed on
RNA from infiltrated liver and spleen of mice injected with
MSCV-hp16 INK4a– infected cells. Expression of hp16 INK4a was unde-
tectable in all eight tumor samples from four different mice. Thirty
nanograms RNA from T- ALL 5 cells infected with MSCV-hp16 INK4a
was used as a positive control. Mouse b - actin RT -PCR served as a
( )control for RNA integrity. C PCR on DNA extracted from leukemic
organs of mice injected with MSCV-hp16 INK4a– infected cells could not
detect the provirus encoded hp16 INK4a gene. A 1-kb ladder is used as
size marker.
Neoplasia v Vol. 1, No. 2, June 1999
Inhibition of T-ALL by p16INK4a Schoppmeyer et al. 135
At the time the experiment was terminated after 100
days, 47% of animals injected with T-ALL 5-hp16INK4a cells
appeared healthy, and pathological analysis revealed no
signs of disease. Pathological analysis of moribund animals
in both the MSCV-hp16INK4a and the MSCV-GFP–treated
groups revealed disseminated leukemia cell invasion involv-
ing the liver, spleen, kidney, lung, and lymph nodes. Fluo-
rescent microscopy of nonfixed organ sections of moribund
mice in the MSCV-GFP–treated control group showed
abundant GFP fluorescence in tissues taken as late as 30
( )days after leukemia cell injection data not shown , indicat-
ing that MSCV retroviral gene expression was maintained in
vivo for the period of the experiment.
Leukemia induced by hp16INK4a -infected cells might have
occurred in spite of the expression of exogenous hp16INK4a,
or it might have resulted from uninfected leukemic cells. To
distinguish between these two possibilities, RNA was iso-
lated from the leukemic livers and spleens of four animals
injected with MSCV-hp16INK4a–infected T-ALL 5 cells and
subjected to RT-PCR with primers specific for human
p16INK4a cDNA. No expression of hp16INK4a message could
( )be detected in any of the organs Figure 5B . PCR-screen-
ing of DNA extracted from these leukemic organs for the
presence of the MSCV-hp16INK4a provirus also yielded neg-
( )ative results Figure 5C . Hence, the leukemias that devel-
oped in mice injected with MSCV-p16INK4a-infected–T-ALL
cells originated from cells that had not been productively
infected prior to injection or from cells that had lost the
MSCV-hp16INK4a provirus.
Discussion
Many similarities exist between human T-ALL and the murine
disease, including the immunophenotype of the leukemic
cells and the occurrence of p53 mutations in advanced
forms of the disease. Here we demonstrate that deletion of
the p15 INK4b, p16 INK4a, and ARF genes, which occurs at a
high frequency in human T-ALL, is also common in murine
( )T-ALL, albeit at a lower frequency 55% versus 18% .
Additionally, we found that six lines with an intact p16 INK4a
gene did not express the p16INK4a protein. Although we
cannot definitively exclude that the lack of p16INK4a protein
expression was due to promoter methylation because the
maximum concentrations of 5-aza-CdR used might have
been too low to demethylate the promoter of the p16 INK4a
gene and induce expression, it has been shown that meth-
INK4a [ ]ylation of the p16 promoter in human T-ALL is rare 5 .
In contrast, silencing by promoter methylation is a common
means of inactivation of the adjacent p15 INK4b gene in both
[ ] [ ]human 5 and murine T-ALL 34 . Hence, our results that 3
of 17 cases had homozygously deleted the gene might be
an underestimation of the frequency by which p15INK4b is
inactivated because we did not assay for protein expres-
sion.
Recently, cases of human T-ALL have been reported in
which p14ARF, the third gene residing at the INK4/ARF
locus, was deleted while either the p16 INK4a or the p15 INK4b
[ ]genes remained unaffected 18 . However, in two of three
reported cases in which p14ARF was deleted but p16INK4a
protein was still produced, the p16INK4a-pRB pathway ap-
peared to be nonfunctional because these samples dis-
played high levels of phosphorylated pRB despite the pres-
ence of p16INK4a. In our murine T-ALL cell lines, we found
that the p19 ARF gene was deleted in 3 of 17 samples, in
parallel with the loss of p16INK4a and p15INK4b and that
p19ARF expression was lost in one additional line.
One explanation for the frequent targeting of the INK4/
ARF locus in T-ALL is the presence of a break-point cluster
region on chromosome 9p21 that predisposes that locus for
( ) [ ]illegitimate V D J recombinational events 18,35 . The re-
sulting growth advantage after deletion of one or more of
the genes residing at the 9p21 locus allows for clonal
[ ]expansion of the affected cell 36 . Eventual disruption of
the other suppressor pathways is likely to be required for full
tumorigenic transformation.
Deletions of the genes encoding p15INK4b, p16INK4a and
p19ARF were found in leukemic cell lines derived from mice
carrying either thymic or disseminated T-ALL, which are
associated with wild-type p53 or mutant p53, respectively
[ ]22 . In the present work we observed a strong correlation
between the presence of wild-type p53 and the loss of
p16INK4a expression. Cell lines retaining at least one copy
of wild-type p53 did not express p16INK4a, whereas 6 out of
7 lines that harbor mutant p53 express p16INK4a. Three of
the lines that possess wild-type p53 lack both p16INK4a and
ARF ( ) ARFp19 T-ALL 4, 5, 46 , thus disrupting the p19 -p53
pathway and relieving the selective pressure for mutation of
p53. However, five of the wild-type p53 lines retained an
intact INK4/ARF gene locus and expressed p19ARF mRNA
but not p16INK4a. The latter may have been deleted during
establishment of the cell lines, consistent with its role in
[ ] INK4areplicative senescence 37 . Alternatively, p16 inactiva-
tion could have been an early event of in vivo tumorigene-
sis. Although loss of p16INK4a does not destabilize the
(genome or facilitate dissemination of the cells as mutant
) [ ] ( )p53 does 22,38 it may be sufficient to enable local thymic
[ ]tumor cell growth without the need for p53 mutation 39 .
Taken together, the results suggest that, as in human T-ALL,
the deletion/ loss of p16INK4a in murine T-ALL can be an
important step in tumorigenesis.
We have shown that re-expression of p16INK4a in INK4/
ARF-negative murine T-ALL cells was sufficient to suppress
the growth of these cells in vitro. On the basis of these
findings and the fact that loss of p16INK4a can be a poor
[ ]prognosticator, particularly in relapse-T-ALL 9 , we exam-
ined the feasibility and effect of T-ALL growth suppression
by p16INK4a in an ex-vivo– in-vivo model, a situation de-
signed to simulate purging of tumor cells in autologous
BMT. We found that nearly 50% of mice injected with T-ALL
cells infected with a recombinant retrovirus expressing
hp16INK4a failed to develop disseminated leukemia, whereas
all of the mice injected with control-treated cells developed
disseminated leukemia in 30 days or less. Neither trans-
gene expression nor provirus could be detected in any of
the tumors that developed in the mice injected with the
hp16INK4a-infected cells, underscoring the selective pres-
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sure against hp16INK4a expression in the leukemic cells.
Because p16INK4a appears to be involved in lymphocyte
senescence, and exogenous p16INK4a expression is capa-
[ ]ble of inducing a differentiated state in lymphoblasts 40,41 ,
we favor the notion that MSCV-hp16INK4a–infected T-ALL
cells underwent permanent growth arrest.
In light of the apparent role of p14ARF in human T-ALL, it
will be interesting to determine the effect of ARF-expression
on in vivo leukemogenicity of T-ALL cells. In vitro, overex-
pression of ARF suppresses proliferation of T-ALL 5 cells
and, surprisingly, to a small but significant degree, the
growth of T-ALL 68 cells, which possess only a mutant p53
( )allele Schoppmeyer and Haas, unpublished results .
It has been reported that restoration of p16INK4a in
p16INK4a-negative/pRB-positive human ALL lines inhibits
[ ]cell growth in culture 42 . Together with our novel finding of
p16INK4a-mediated T-ALL growth suppression in vivo, these
results suggest that p16 INK4a gene transfer into residual
leukemic bone marrow cells before autologous BMT may be
used to inhibit leukemia cell growth and further reduce the
incidence of post-transplant leukemia relapse. Future stud-
ies demonstrating the suppression of human T-ALL cell
growth by p16INK4a in a SCID mouse model are needed to
support this idea.
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